Form 4: Entrada Therapeutics CEO Dipal Doshi Reports Stock Sales to Cover Tax Obligations
SEC Form 4 Filing
Entrada Therapeutics CEO Dipal Doshi sold shares of common stock between September 3rd and September 5th, 2024, to cover tax obligations arising from the vesting of restricted stock units.
Summary
- Dipal Doshi, CEO of Entrada Therapeutics, reported the sale of common stock between September 3rd and September 5th, 2024.
- The sales were executed to cover minimum statutory tax withholding obligations due upon the vesting and settlement of restricted stock units.
- A total of 9,422 shares were sold across multiple transactions at varying prices.
- The sales were not discretionary trades but were mandated by a sell-to-cover provision in the award agreement.
- The weighted average sale prices ranged from $15.126 to $17.702 per share.
- Following the reported transactions, Doshi beneficially owns 325,753 shares of Entrada Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing stock sales for tax purposes, which is neither particularly positive nor negative.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.
Stakeholder Impact
- The stock sales could have a minor dilutive effect on existing shareholders.
Key Dates
| Date | Description |
|---|---|
| 09/03/2024 | Date of first reported transaction (stock sale). |
| 09/04/2024 | Date of a reported transaction (stock sale). |
| 09/05/2024 | Date of last reported transaction (stock sale) and signature date of the Form 4. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.